HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies
Authors:
Open Access
- 1 July 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Hepatitis B virus reactivation (HBV-R), which can lead to HBV-related morbidity and mortality, is a common and well-known complication that occurs during the treatment of non-Hodgkin lymphoma (NHL) patients with current or past exposure to HBV infection. HBV-R is thought to be closely associated with chemotherapeutic or immunosuppressive therapies. However, immunosuppressive agents such as anti-CD20 antibodies (e.g., rituximab and ofatumumab), glucocorticoids, and hematopoietic stem cell transplantation (HSCT) administered to NHL patients during treatment can cause deep immunodepression and place them at high risk of HBV-R. In this review, we explore the current evidence, the guidelines of several national and international organizations, and the recommendations of expert panels relating to the definition, risk factors, screening and monitoring strategies, whether to use prophylaxis or pre-emptive therapy, and the optimal antiviral agent and duration of antiviral therapy for HBV-R.Keywords
This publication has 99 references indexed in Scilit:
- Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer centerBMC Cancer, 2013
- Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin’s Lymphoma after ChemotherapyPLOS ONE, 2013
- A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experienceClinical and Molecular Hepatology, 2013
- Low Rates of Hepatitis B Virus Screening at the Onset of ChemotherapyJournal of Oncology Practice, 2012
- Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reportsAnnals of Oncology, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancerJournal of Viral Hepatitis, 2009
- Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenanceHaematologica, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantationBone Marrow Transplantation, 2002